

# LexaGene Holdings Inc.

08:50 17 Sep 2019

## LexaGene develops test for deadly mosquito-borne Eastern Equine Encephalitis virus

LexaGene Holdings Inc (CVE:LXG) (OTCMKTS:LXXGF) announced Tuesday the development of a test to detect the deadly Eastern Equine Encephalitis (EEE) virus on its LX technology platform.

The EEE virus can be transmitted through the bite of an infected mosquito, and has recently caused fatal infections in Michigan, Massachusetts and Rhode Island, the company said in a statement.

The virus is particularly serious for both children and the elderly and can lead to death in approximately 30% of infected individuals.

### READ: LexaGene's LX Analyzer to be tested in one of the largest hemp-cannabis labs in Massachusetts

Northeastern states typically test in excess of 15,000 samples per year for EEE. This year, Massachusetts state testing labs alone have processed thousands of samples of which more than 400 mosquito samples were found to be positive for the presence of EEE virus.

Previously, LexaGene's technology was only able to detect DNA-based pathogens.

Now the company said it has modified the analyzer to also detect pathogens that have RNA-based genomes. Examples of pathogens that have RNA-based genomes include EEE and other mosquito-borne viruses such as West Nile, Chikungunya and Zika viruses, as well as other deadly pathogens such as influenza and Ebola.

Another benefit of the LX Analyzer, the Massachusetts-based company said, is its ability to screen for multiple pathogens at once, which is critical for carrying out successful screening programs of mosquito populations for vector-borne viruses.

"Testing mosquitoes for the presence of human pathogens is an integral part of surveillance activities. We have now used our LX Analyzer to successfully amplify the EEE virus sequence from mosquito RNA samples spiked with EEE RNA," said CEO Dr Jack Regan.

"Our technology is automated and designed to reduce hands-on processing time, which is a benefit to molecular testing laboratories. We are pursuing this work to demonstrate that LexaGene's technology can be part of the solution for bolstering surveillance efforts intended to determine when mosquito abatement programs should be started to minimize the number of human cases."


LexaGene said it welcomes members of the public, including businesses and testing laboratories, to send mosquitoes to their laboratory for testing.

Contact the author: [patrick@proactiveinvestors.com](mailto:patrick@proactiveinvestors.com)

**Price:** 0.86

**Market Cap:** \$97.79 m

### 1 Year Share Price Graph



December 2019 June 2020 November 20

### Share Information

**Code:** LXG

**Listing:** TSX-V

<b>52 week</b>	<b>High</b>	<b>Low</b>
	1.28	0.43

**Sector:** Medical technology & services

**Website:** [www.lexagene.com](http://www.lexagene.com)

### Company Synopsis:

*LexaGene is a biotechnology company developing a fully automated pathogen detection platform for use at the site of sample collection, which offers unprecedented ease-of-use, sensitivity, and breadth of pathogen detection.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Follow him on Twitter @PatrickMGraham

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of LexaGene Holdings Inc. named herein, including the promotion by the Company of LexaGene Holdings Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).